# immunotherapy
Latest news and articles about immunotherapy
Total: 4 articles found
Portuguese Team Recreates Anti‑Cancer Immune Cells in the Lab, Opening New Path for Cell Therapies
A research team involving the University of Coimbra reports that they have recreated immune cells with anti‑tumour activity in the lab using cellular reprogramming. The result is a preclinical milestone that could broaden the toolbox for cancer cell therapies but requires peer review, animal studies and clinical trials before clinical application.
Chinese teams unmask a metabolic immune‑escape — and a path toward lab‑made anti‑tumour T cells
Chinese research teams identified extracellular CD44 lactylation as a mechanism by which tumour‑generated lactate blunts CD8+ T cell function, revealing a direct metabolic route to immune escape. The discovery suggests new therapeutic strategies — including drugs or engineered T cells resistant to lactylation — but remains at the preclinical stage.
Painless Patch for Immune Cells: Microneedle Device Promises Non‑Invasive Immune Monitoring
A collaboration between The Jackson Laboratory and MIT has produced a microneedle patch that non‑invasively samples immune cells from humans, enabling painless, repeatable collection for laboratory analysis. Published in Nature Biomedical Engineering, the device could reshape immune monitoring in clinical trials, vaccine development and personalised medicine, though validation, regulatory approval and ethical safeguards are still required.
Merck’s PD‑1 Drug Pembrolizumab Wins China Approval as First‑Line Option for dMMR Advanced Endometrial Cancer
Merck’s pembrolizumab (KeRuida®) has been approved by China’s NMPA for first‑line use with carboplatin and paclitaxel, followed by pembrolizumab maintenance, in adults with dMMR advanced or recurrent endometrial cancer. The approval, based on phase III KEYNOTE‑868 (NRG‑GY018) data, shifts immunotherapy into the front line for this biomarker‑defined subgroup and raises issues of testing, reimbursement and market competition.